FDA announces guidance for industry titled Changes to Disposable Manufacturing Materials: Questions and Answers

July 29, 2022

Today, FDA is announcing the availability of a level 2 guidance for industry titled, Changes to Disposable Manufacturing Materials: Questions and Answers. FDA receives questions about the limited availability of disposable manufacturing materials during periods of increased demand (e.g., public health emergencies or natural disasters). Limited availability of disposable manufacturing materials can affect sterile drugs and biological products. This guidance describes chemistry, manufacturing, and controls (CMC) post-approval changes related to disposable manufacturing materials that applicants can pursue in drug and biological product manufacturing. Applicants should use science-based and risk-based principles, and current FDA guidances for industry, to determine the appropriate reporting category to communicate changes to disposable manufacturing materials.

This guidance applies to biologics license application (BLA) products; human drug products marketed as new drug applications (NDAs) or abbreviated new drug applications (ANDAs); and animal drugs marketed as new animal drug applications (NADAs) or abbreviated new animal drug applications (ANADAs). This guidance also applies to all manufacturing establishments, including those that perform functions under contract as defined in the guidance for industry Contract Manufacturing Arrangements for Drugs: Quality Agreements.

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.

 




General Regulatory Regulatory Sciences

July 29, 2022

Draft Guidance for Microbial Vectors Used for Gene Therapy Outlines FDA Safety Concerns

Issues for Sponsors with INDs and CMC concerns FDA recently released a draft guidance entitled “Recommendations for Microbial Vectors Used for Gene Therapy” as a supplemental guidance to “Guidance...

Read More
Regulatory Sciences

July 29, 2022

Now May be the Time to Approach the FDA Regarding CMC and Nonclinical Questions – Giving These Topics the Attention they Deserve

Due to the current regulatory landscape that has been created by the COVID-19 pandemic, clinical trials have been disrupted across the globe.  To many Sponsors, this may feel like a loss of progress...

Read More
Life Science Consulting Clinical Research Solutions

July 29, 2022

Top Questions & Answers for Managing the New IVDR

With an increased need for high quality in vitro diagnostic medical devices (IVDs), the In Vitro Diagnostic Regulation (IVDR, 2017/746) was entered into force for all IVDs in 2017 with a five-year...

Read More